Tempest Therapeutics Inc (TPST)

$7.13 0.00 (N/A)
Market Cap 26.26M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 48,600
Avg Vol 128,734
Day's Range N/A - N/A
Shares Out 3.68M
Stochastic %K 81%
Beta -1.95
Analysts Sell
Price Target $9.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Michl2000
Michl2000 Jul. 7 at 3:24 PM
$TPST having a look at the share price you can be quite sure that there aren't many, that assume a big buyout in the near furure
1 · Reply
BiotechBreakout
BiotechBreakout Jul. 7 at 2:39 PM
$TPST I’m waiting Brady….
2 · Reply
lousjamsession
lousjamsession Jul. 7 at 2:28 PM
$TPST
0 · Reply
brunoq14
brunoq14 Jul. 7 at 2:08 PM
$TPST Can we get a decent price for this if the FAP trial is successful?
1 · Reply
Westieofwallst
Westieofwallst Jul. 7 at 1:42 PM
$TPST 1495 trial estimated start date of 05-28-2025 had held for months until it was updated on 06-28 to a relatively short turnaround date of 07-14-2025... might that indicate something about timeline?
2 · Reply
MindsEye66
MindsEye66 Jul. 7 at 1:08 PM
$TPST Other than letting this percolate a little this is ready for the news !
0 · Reply
WeAllFallDown
WeAllFallDown Jul. 7 at 11:30 AM
$TPST
0 · Reply
lgb2
lgb2 Jul. 7 at 10:55 AM
$TPST $.60
1 · Reply
lgb2
lgb2 Jul. 7 at 10:55 AM
$TPST 💩
0 · Reply
Quinnzilla
Quinnzilla Jul. 7 at 10:50 AM
$TPST
0 · Reply
Latest News on TPST
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 7 days ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 26 days ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 4 weeks ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 7 weeks ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 2 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 2 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 3 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 3 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 3 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 4 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 5 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 5 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 6 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 7 months ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 8 months ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 9 months ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 9 months ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 10 months ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 10 months ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 11 months ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 11 months ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 1 year ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 1 year ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 1 year ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 1 year ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 1 year ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 1 year ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Oct 10, 2023, 4:05 PM EDT - 1 year ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest to Present at the Jefferies Global Healthcare Conference

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Apr 26, 2023, 6:41 PM EDT - 2 years ago

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Mar 22, 2023, 5:26 PM EDT - 2 years ago

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 4:05 PM EST - 2 years ago

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 8, 2022, 8:00 AM EST - 2 years ago

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Michl2000
Michl2000 Jul. 7 at 3:24 PM
$TPST having a look at the share price you can be quite sure that there aren't many, that assume a big buyout in the near furure
1 · Reply
BiotechBreakout
BiotechBreakout Jul. 7 at 2:39 PM
$TPST I’m waiting Brady….
2 · Reply
lousjamsession
lousjamsession Jul. 7 at 2:28 PM
$TPST
0 · Reply
brunoq14
brunoq14 Jul. 7 at 2:08 PM
$TPST Can we get a decent price for this if the FAP trial is successful?
1 · Reply
Westieofwallst
Westieofwallst Jul. 7 at 1:42 PM
$TPST 1495 trial estimated start date of 05-28-2025 had held for months until it was updated on 06-28 to a relatively short turnaround date of 07-14-2025... might that indicate something about timeline?
2 · Reply
MindsEye66
MindsEye66 Jul. 7 at 1:08 PM
$TPST Other than letting this percolate a little this is ready for the news !
0 · Reply
WeAllFallDown
WeAllFallDown Jul. 7 at 11:30 AM
$TPST
0 · Reply
lgb2
lgb2 Jul. 7 at 10:55 AM
$TPST $.60
1 · Reply
lgb2
lgb2 Jul. 7 at 10:55 AM
$TPST 💩
0 · Reply
Quinnzilla
Quinnzilla Jul. 7 at 10:50 AM
$TPST
0 · Reply
HappyGentelmen
HappyGentelmen Jul. 7 at 9:53 AM
$TPST Looking nice today!
0 · Reply
Michl2000
Michl2000 Jul. 7 at 7:50 AM
$TPST my price target for this week. What do you guess?
0 · Reply
LoUber
LoUber Jul. 7 at 3:00 AM
$TPST *A Public Service Announcement: @think101 is our old 'pal' @Harleybug and his very feeble attempt, to reinvent himself here on this board with a new moniker. Nice try ..'pal'! ; )
0 · Reply
think101
think101 Jul. 7 at 2:30 AM
$TPST what kind of BO.. chill out..
1 · Reply
lgb2
lgb2 Jul. 7 at 2:21 AM
$TPST not to worry there are suckers born every day
0 · Reply
lgb2
lgb2 Jul. 7 at 2:17 AM
$TPST I think he made a mistake. He uses cyanide pill instead of a poison pill.
0 · Reply
sanabu
sanabu Jul. 7 at 1:40 AM
$TPST is this a concern?
3 · Reply
arask
arask Jul. 7 at 1:19 AM
$TPST everyone on this board is hoping for a July announcement.. gl everyone , stay patient and add when you can
1 · Reply
lgb2
lgb2 Jul. 6 at 10:20 PM
$TPST he’ll tell you or us soon as he gets back from Fiji
0 · Reply
lgb2
lgb2 Jul. 6 at 10:19 PM
$TPST you know that people that always talk about buyout and mergers. I think they smell it the buyout offers when they’re sitting on the toilet bowl.
0 · Reply
lgb2
lgb2 Jul. 6 at 10:03 PM
$TPST buy out tomorrow morning definitely I think $1.99 a share plus by two toilet bowls with toilet paper
0 · Reply
GreylockSec
GreylockSec Jul. 6 at 9:15 PM
$TPST ...This is AMAZING news, and subsequently indicates that Roche is still on board, and not going to pull the medicine and/or pull out of the supply agreement - which means all systems are go, for a big corporate sale for Tempest!..
2 · Reply